Stockholders approve stock issuance on conversion of Series A Preferred for Pionyr acquisition

ImageneBio, Inc.

Special meeting on October 11, 2023; 37,464,898 shares outstanding.
Proposal 1 (stock issuance on conversion of Series A Preferred) approved: 25,681,604 for, 12,086 against, 1,156 abstain.
1,647,531 shares excluded from Nasdaq vote but counted under Delaware law.
Proposal 2 (adjournment if needed) approved: 26,947,409 for, 394,239 against, 729 abstain.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

ImageneBio, Inc. shareholders approved Issuance of common stock upon conversion of Series A Non-Voting Convertible Preferred Stock in connection with the acquisition of Pionyr Immunotherapeutics, Inc. at the 2023-10-11 meeting.

Outcome: passed
Meeting: 2023-10-11

Exact text from the filing

The Company’s stockholders approved, in accordance with Nasdaq Listing Rule 5635(a), the issuance of the Company’s common stock, par value $0.001 per share (“Common Stock”), upon conversion of the Company’s Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share (“Proposal No. 1"), issued in connection with the acquisition of Pionyr Immunotherapeutics, Inc. (the “Acquisition”). The votes cast at the Special Meeting were as follows: For Against Abstain 25,681,604 12,086 1,156

View on SEC.gov

215 shareholder votes filed in the last 30 days. Browse all shareholder votes →

ImageneBio, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-047880

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.